Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 516

1.

Clinical impact of skeletal muscle area in patients with non-small cell lung cancer treated with anti-PD-1 inhibitors.

Takada K, Yoneshima Y, Tanaka K, Okamoto I, Shimokawa M, Wakasu S, Takamori S, Toyokawa G, Oba T, Osoegawa A, Tagawa T, Oda Y, Nakanishi Y, Mori M.

J Cancer Res Clin Oncol. 2020 Feb 5. doi: 10.1007/s00432-020-03146-5. [Epub ahead of print]

PMID:
32025867
2.

Impact of somatic mutations on prognosis in resected non-small-cell lung cancer: The Japan Molecular Epidemiology for lung cancer study.

Tamiya A, Koh Y, Isa SI, Kubo A, Ando M, Saka H, Yoshimoto N, Takeo S, Adachi H, Tagawa T, Kawashima O, Yamashita M, Kataoka K, Takenoyama M, Takeuchi Y, Watanabe K, Matsumura A, Kawaguchi T.

Cancer Med. 2020 Feb 5. doi: 10.1002/cam4.2897. [Epub ahead of print]

3.

Combined Evaluation of Tumor-Infiltrating CD8 + and FoxP3 + Lymphocytes Provides Accurate Prognosis in Stage IA Lung Adenocarcinoma.

Kinoshita F, Takada K, Yamada Y, Oku Y, Kosai K, Ono Y, Tanaka K, Wakasu S, Oba T, Osoegawa A, Tagawa T, Shimokawa M, Oda Y, Mori M.

Ann Surg Oncol. 2019 Nov 26. doi: 10.1245/s10434-019-08029-9. [Epub ahead of print]

PMID:
31773516
4.

Prognostic Impact of Postoperative Skeletal Muscle Decrease in Non-Small Cell Lung Cancer.

Takamori S, Tagawa T, Toyokawa G, Shimokawa M, Kinoshita F, Kozuma Y, Matsubara T, Haratake N, Akamine T, Hirai F, Honda H, Maehara Y.

Ann Thorac Surg. 2019 Oct 23. pii: S0003-4975(19)31595-4. doi: 10.1016/j.athoracsur.2019.09.035. [Epub ahead of print]

PMID:
31655044
5.

18F-FDG uptake in PET/CT is a potential predictive biomarker of response to anti-PD-1 antibody therapy in non-small cell lung cancer.

Takada K, Toyokawa G, Yoneshima Y, Tanaka K, Okamoto I, Shimokawa M, Wakasu S, Haro A, Osoegawa A, Tagawa T, Oda Y, Nakanishi Y, Mori M.

Sci Rep. 2019 Sep 16;9(1):13362. doi: 10.1038/s41598-019-50079-2.

6.

The evolution of surgical treatment for gastrointestinal cancers.

Maehara Y, Soejima Y, Yoshizumi T, Kawahara N, Oki E, Saeki H, Akahoshi T, Ikegami T, Yamashita YI, Furuyama T, Sugimachi K, Harada N, Tagawa T, Harimoto N, Itoh S, Sonoda H, Ando K, Nakashima Y, Nagao Y, Yamashita N, Kasagi Y, Yukaya T, Kurihara T, Tsutsumi R, Takamori S, Sasaki S, Ikeda T, Yonemitsu Y, Fukuhara T, Kitao H, Iimori M, Kataoka Y, Wakasa T, Suzuki M, Teraishi K, Yoshida Y, Mori M.

Int J Clin Oncol. 2019 Nov;24(11):1333-1349. doi: 10.1007/s10147-019-01499-7. Epub 2019 Sep 14.

PMID:
31522313
7.

[Resection of Lung Cancer with Chest Wall Invasion Using Posterior Paramedian Incision].

Doi R, Machino R, Tokunaga T, Tsuji H, Tagawa T, Nagayasu T.

Kyobu Geka. 2019 Sep;72(9):669-672. Japanese.

PMID:
31506407
8.

Efficacy of Full-Spectrum Endoscopy to Visualize the Major Duodenal Papilla in Patients with Familial Adenomatous Polyposis.

Ichijima R, Abe S, Kobayashi S, Minagawa T, Tagawa T, Nakajima T, Yamada M, Takamaru H, Sekiguchi M, Sakamoto T, Oda I, Matsuda T, Saito Y, Gotoda T.

Digestion. 2019 Jul 16:1-8. doi: 10.1159/000501476. [Epub ahead of print]

PMID:
31311010
9.

Pulmonary metastasis presenting as a ground glass opacity-like lesion with a thin-walled cavity: A case report.

Haro A, Wakasu S, Takada K, Osoegawa A, Kamitani T, Tagawa T, Mori M.

Int J Surg Case Rep. 2019;60:287-290. doi: 10.1016/j.ijscr.2019.06.030. Epub 2019 Jun 21.

10.

Microscopy Reveals: Impact of Lithium Salts on Elementary Steps Predicts Organozinc Reagent Synthesis and Structure.

Jess K, Kitagawa K, Tagawa TKS, Blum SA.

J Am Chem Soc. 2019 Jun 26;141(25):9879-9884. doi: 10.1021/jacs.9b02639. Epub 2019 Jun 12.

PMID:
31188579
11.

Association between peripheral blood markers and immune-related factors on tumor cells in patients with resected primary lung adenocarcinoma.

Takada K, Shimokawa M, Tanaka K, Kohashi K, Haro A, Osoegawa A, Tagawa T, Azuma K, Okamoto I, Oda Y, Mori M.

PLoS One. 2019 Jun 4;14(6):e0217991. doi: 10.1371/journal.pone.0217991. eCollection 2019.

12.

The Influence of Clinical T Factor on Predicting Pathologic N Factor in Resected Lung Cancer.

Shimamatsu S, Takenoyama M, Shimokawa M, Takada K, Edagawa M, Toyozawa R, Nosaki K, Oba T, Tagawa T, Yamaguchi M, Taguchi K, Seto T.

Ann Thorac Surg. 2019 Oct;108(4):1080-1086. doi: 10.1016/j.athoracsur.2019.04.026. Epub 2019 May 16.

PMID:
31103386
13.

Clinical and Prognostic Significance of the Epithelial-Mesenchymal Transition in Stage IA Lung Adenocarcinoma: A Propensity Score-Matched Analysis.

Matsubara T, Tagawa T, Takada K, Toyokawa G, Shimokawa M, Kozuma Y, Akamine T, Haro A, Osoegawa A, Mori M.

Clin Lung Cancer. 2019 Jul;20(4):e504-e513. doi: 10.1016/j.cllc.2019.04.006. Epub 2019 Apr 19.

PMID:
31103348
14.

Prognosis of Early-stage Part-solid and Pure-solid Lung Adenocarcinomas.

Kinoshita F, Toyokawa G, Matsubara T, Kozuma Y, Haratake N, Takamori S, Akamine T, Hirai F, Takenaka T, Tagawa T, Maehara Y.

Anticancer Res. 2019 May;39(5):2665-2670. doi: 10.21873/anticanres.13391.

PMID:
31092466
15.

The association and prognostic impact of enhancer of zeste homologue 2 expression and epithelial-mesenchymal transition in resected lung adenocarcinoma.

Matsubara T, Toyokawa G, Takada K, Kinoshita F, Kozuma Y, Akamine T, Shimokawa M, Haro A, Osoegawa A, Tagawa T, Mori M.

PLoS One. 2019 May 1;14(5):e0215103. doi: 10.1371/journal.pone.0215103. eCollection 2019.

16.

A novel prognostic marker in patients with non-small cell lung cancer: musculo-immuno-nutritional score calculated by controlling nutritional status and creatine kinase.

Takamori S, Toyokawa G, Shimokawa M, Kinoshita F, Kozuma Y, Matsubara T, Haratake N, Akamine T, Hirai F, Tagawa T, Oda Y, Maehara Y.

J Thorac Dis. 2019 Mar;11(3):927-935. doi: 10.21037/jtd.2019.01.76.

17.

Association of Low Body Mass Index With Poor Clinical Outcomes After Resection of Non-small Cell Lung Cancer.

Takada K, Shimokawa M, Akamine T, Ono Y, Haro A, Osoegawa A, Tagawa T, Mori M.

Anticancer Res. 2019 Apr;39(4):1987-1996. doi: 10.21873/anticanres.13309.

PMID:
30952742
18.

BZLF1 interacts with chromatin remodelers promoting escape from latent infections with EBV.

Schaeffner M, Mrozek-Gorska P, Buschle A, Woellmer A, Tagawa T, Cernilogar FM, Schotta G, Krietenstein N, Lieleg C, Korber P, Hammerschmidt W.

Life Sci Alliance. 2019 Mar 29;2(2). pii: e201800108. doi: 10.26508/lsa.201800108. Print 2019 Apr.

19.

Lorlatinib for the treatment of patients with non-small cell lung cancer.

Akamine T, Toyokawa G, Tagawa T, Yamazaki K, Seto T, Takeo S, Mori M.

Drugs Today (Barc). 2019 Feb;55(2):107-116. doi: 10.1358/dot.2019.55.2.2927983.

PMID:
30816885
20.

A Clinicopathological and Prognostic Analysis of PD-L2 Expression in Surgically Resected Primary Lung Squamous Cell Carcinoma.

Matsubara T, Takada K, Azuma K, Takamori S, Toyokawa G, Haro A, Osoegawa A, Tagawa T, Kawahara A, Akiba J, Okamoto I, Nakanishi Y, Oda Y, Hoshino T, Maehara Y.

Ann Surg Oncol. 2019 Jun;26(6):1925-1933. doi: 10.1245/s10434-019-07257-3. Epub 2019 Feb 27.

PMID:
30815803
21.

Prognostic Impact of Programmed Death-Ligand 2 Expression in Primary Lung Adenocarcinoma Patients.

Takamori S, Takada K, Azuma K, Jogo T, Shimokawa M, Toyokawa G, Hirai F, Tagawa T, Kawahara A, Akiba J, Okamoto I, Nakanishi Y, Oda Y, Hoshino T, Maehara Y.

Ann Surg Oncol. 2019 Jun;26(6):1916-1924. doi: 10.1245/s10434-019-07231-z. Epub 2019 Feb 27.

PMID:
30815801
22.

The Significance of CD44 Variant 9 in Resected Lung Adenocarcinoma: Correlation with Pathological Early-Stage and EGFR Mutation.

Akamine T, Tagawa T, Ijichi K, Toyokawa G, Takamori S, Hirai F, Okamoto T, Oda Y, Maehara Y.

Ann Surg Oncol. 2019 May;26(5):1544-1551. doi: 10.1245/s10434-018-07137-2. Epub 2019 Feb 24.

PMID:
30798450
23.

Localized malignant pleural mesothelioma mimicking an anterior mediastinal tumor.

Hino T, Kamitani T, Sagiyama K, Yamasaki Y, Okamoto I, Tagawa T, Ijichi K, Yamamoto H, Yabuuchi H, Honda H.

Eur J Radiol Open. 2019 Jan 31;6:72-77. doi: 10.1016/j.ejro.2019.01.006. eCollection 2019.

24.

Pomalidomide increases immune surface marker expression and immune recognition of oncovirus-infected cells.

Davis DA, Shrestha P, Aisabor AI, Stream A, Galli V, Pise-Masison CA, Tagawa T, Ziegelbauer JM, Franchini G, Yarchoan R.

Oncoimmunology. 2018 Dec 5;8(2):e1546544. doi: 10.1080/2162402X.2018.1546544. eCollection 2019.

25.

Intraoperative diagnosis of an unsuspected ruptured left ventricular aneurysm using transesophageal echocardiography: A case report.

Tagawa T, Sakuraba S.

Clin Case Rep. 2018 Nov 11;7(1):37-39. doi: 10.1002/ccr3.1902. eCollection 2019 Jan.

26.

Co-expression of IDO1 and PD-L1 in lung squamous cell carcinoma: Potential targets of novel combination therapy.

Takada K, Kohashi K, Shimokawa M, Haro A, Osoegawa A, Tagawa T, Seto T, Oda Y, Maehara Y.

Lung Cancer. 2019 Feb;128:26-32. doi: 10.1016/j.lungcan.2018.12.008. Epub 2018 Dec 10.

PMID:
30642449
27.

The prognostic impact of obstructive lung disease on survival of never smokers with resected non-small-cell lung cancer: a comparison with smokers.

Akamine T, Tagawa T, Shimokawa M, Matsubara T, Kozuma Y, Haratake N, Takamori S, Toyokawa G, Maehara Y.

Interact Cardiovasc Thorac Surg. 2019 May 1;28(5):735-743. doi: 10.1093/icvts/ivy329.

PMID:
30602039
28.

Spatiotemporally Skewed Activation of Programmed Cell Death Receptor 1-Positive T Cells after Epstein-Barr Virus Infection and Tumor Development in Long-Term Fully Humanized Mice.

Danisch S, Slabik C, Cornelius A, Albanese M, Tagawa T, Chen YA, Krönke N, Eiz-Vesper B, Lienenklaus S, Bleich A, Theobald SJ, Schneider A, Ganser A, von Kaisenberg C, Zeidler R, Hammerschmidt W, Feuerhake F, Stripecke R.

Am J Pathol. 2019 Mar;189(3):521-539. doi: 10.1016/j.ajpath.2018.11.014. Epub 2018 Dec 26.

29.

HMGB1 blockade significantly improves luminal fibrous obliteration in a murine model of bronchiolitis obliterans syndrome.

Takamori S, Shoji F, Okamoto T, Kozuma Y, Matsubara T, Haratake N, Akamine T, Katsura M, Takada K, Toyokawa G, Tagawa T, Maehara Y.

Transpl Immunol. 2019 Apr;53:13-20. doi: 10.1016/j.trim.2018.11.007. Epub 2018 Dec 1.

PMID:
30508580
30.

Discovery of Kaposi's sarcoma herpesvirus-encoded circular RNAs and a human antiviral circular RNA.

Tagawa T, Gao S, Koparde VN, Gonzalez M, Spouge JL, Serquiña AP, Lurain K, Ramaswami R, Uldrick TS, Yarchoan R, Ziegelbauer JM.

Proc Natl Acad Sci U S A. 2018 Dec 11;115(50):12805-12810. doi: 10.1073/pnas.1816183115. Epub 2018 Nov 19.

31.

Differences in PD-L1 expression on tumor and immune cells between lung metastases and corresponding primary tumors.

Takamori S, Takada K, Tagawa T, Toyokawa G, Hirai F, Yamashita N, Okamoto T, Oki E, Yoshizumi T, Oda Y, Maehara Y.

Surg Oncol. 2018 Dec;27(4):637-641. doi: 10.1016/j.suronc.2018.08.001. Epub 2018 Aug 11.

PMID:
30449485
32.

Atezolizumab in non-squamous non-small cell lung cancer.

Akamine T, Toyokawa G, Tagawa T, Seto T.

J Thorac Dis. 2018 Sep;10(Suppl 26):S3155-S3159. doi: 10.21037/jtd.2018.07.92. No abstract available.

33.

Radiological Features of Programmed Cell Death-Ligand 2-positive Lung Adenocarcinoma: A Single-institution Retrospective Study.

Takada K, Toyokawa G, Azuma K, Takamori S, Jogo T, Hirai F, Tagawa T, Kawahara A, Akiba J, Okamoto I, Nakanishi Y, Oda Y, Hoshino T, Maehara Y.

In Vivo. 2018 Nov-Dec;32(6):1541-1550. doi: 10.21873/invivo.11412.

34.

A Positive Correlation Between the EZH2 and PD-L1 Expression in Resected Lung Adenocarcinomas.

Toyokawa G, Takada K, Tagawa T, Hamamoto R, Yamada Y, Shimokawa M, Oda Y, Maehara Y.

Ann Thorac Surg. 2019 Feb;107(2):393-400. doi: 10.1016/j.athoracsur.2018.08.056. Epub 2018 Oct 18.

PMID:
30343006
35.

Prognostic Impact of PD-L2 Expression and Association with PD-L1 in Patients with Small-cell Lung Cancer.

Takamori S, Takada K, Azuma K, Jogo Y, Kinoshita F, Kozuma Y, Matsubara T, Haratake N, Akamine T, Toyokawa G, Hirai F, Tagawa T, Okamoto I, Nakanishi Y, Kawahara A, Akiba J, Oda Y, Maehara Y.

Anticancer Res. 2018 Oct;38(10):5903-5907. doi: 10.21873/anticanres.12934.

PMID:
30275217
36.

PD-L2 Expression as a Potential Predictive Biomarker for the Response to Anti-PD-1 Drugs in Patients with Non-small Cell Lung Cancer.

Takamori S, Takada K, Toyokawa G, Azuma K, Shimokawa M, Jogo T, Yamada Y, Hirai F, Tagawa T, Kawahara A, Akiba J, Okamoto I, Nakanishi Y, Oda Y, Hoshino T, Maehara Y.

Anticancer Res. 2018 Oct;38(10):5897-5901. doi: 10.21873/anticanres.12933.

PMID:
30275216
37.

miR-3148 Is a Novel Onco-microRNA that Potentiates Tumor Growth In Vivo.

Akamine T, Morodomi Y, Harada Y, Teraishi K, Tagawa T, Okamoto T, Maehara Y, Yonemitsu Y.

Anticancer Res. 2018 Oct;38(10):5693-5701. doi: 10.21873/anticanres.12906.

PMID:
30275189
38.

A phase II randomized trial of adjuvant chemotherapy with S-1 versus S-1 plus cisplatin for completely resected pathological stage II/IIIA non-small cell lung cancer.

Okamoto T, Yano T, Shimokawa M, Takeo S, Yamazaki K, Sugio K, Takenoyama M, Nagashima A, Tsukamoto S, Hamatake M, Yokoyama H, Ueda H, Motohiro A, Tagawa T, Shoji F, Kometani T, Saito G, Fukuyama Y, Toyokawa G, Osoegawa A, Emi Y, Maehara Y; Kyushu University Lung Surgery Study Group (KLSS) Japan.

Lung Cancer. 2018 Oct;124:255-259. doi: 10.1016/j.lungcan.2018.08.015. Epub 2018 Aug 19.

PMID:
30268470
39.

Radiological Features of IDO1+/PDL1+ Lung Adenocarcinoma: A Retrospective Single-institution Study.

Takada K, Toyokawa G, Tagawa T, Shimokawa M, Kohashi K, Haro A, Osoegawa A, Oda Y, Maehara Y.

Anticancer Res. 2018 Sep;38(9):5295-5303. doi: 10.21873/anticanres.12856.

PMID:
30194181
40.

Spotlight on lorlatinib and its potential in the treatment of NSCLC: the evidence to date.

Akamine T, Toyokawa G, Tagawa T, Seto T.

Onco Targets Ther. 2018 Aug 22;11:5093-5101. doi: 10.2147/OTT.S165511. eCollection 2018. Review.

41.

Significance of spread through air spaces in early-stage lung adenocarcinomas undergoing limited resection.

Toyokawa G, Yamada Y, Tagawa T, Oda Y.

Thorac Cancer. 2018 Oct;9(10):1255-1261. doi: 10.1111/1759-7714.12828. Epub 2018 Aug 6.

42.

Indoleamine 2,3-dioxygenase 1 and programmed cell death-ligand 1 co-expression correlates with aggressive features in lung adenocarcinoma.

Kozuma Y, Takada K, Toyokawa G, Kohashi K, Shimokawa M, Hirai F, Tagawa T, Okamoto T, Oda Y, Maehara Y.

Eur J Cancer. 2018 Sep;101:20-29. doi: 10.1016/j.ejca.2018.06.020. Epub 2018 Jul 13.

PMID:
30014971
43.

Recurrent idiopathic pulmonary hemosiderosis after long-term remission presented with Sjogren's syndrome: Idiopathic no more?

Yanagihara T, Yamamoto Y, Hamada N, Suzuki K, Ogata-Suetsugu S, Harada E, Tagawa T, Fujiwara M, Hashisako M, Fukuoka J, Nakanishi Y.

Respir Med Case Rep. 2018 Jun 30;25:68-72. doi: 10.1016/j.rmcr.2018.06.013. eCollection 2018.

44.

Computed tomography features of resected lung adenocarcinomas with spread through air spaces.

Toyokawa G, Yamada Y, Tagawa T, Kamitani T, Yamasaki Y, Shimokawa M, Oda Y, Maehara Y.

J Thorac Cardiovasc Surg. 2018 Oct;156(4):1670-1676.e4. doi: 10.1016/j.jtcvs.2018.04.126. Epub 2018 Jun 6.

PMID:
29961590
45.

Stevens-Johnson Syndrome Induced by Pembrolizumab in a Lung Cancer Patient.

Haratake N, Tagawa T, Hirai F, Toyokawa G, Miyazaki R, Maehara Y.

J Thorac Oncol. 2018 Nov;13(11):1798-1799. doi: 10.1016/j.jtho.2018.05.031. Epub 2018 Jun 6. No abstract available.

46.

Radiological Features of Brain Metastases from Non-small Cell Lung Cancer Harboring EGFR Mutation.

Takamori S, Toyokawa G, Shimokawa M, Kinoshita F, Kozuma Y, Matsubara T, Haratake N, Akamine T, Mukae N, Hirai F, Tagawa T, Oda Y, Iwaki T, Iihara K, Honda H, Maehara Y.

Anticancer Res. 2018 Jun;38(6):3731-3734. doi: 10.21873/anticanres.12653.

PMID:
29848735
47.

Prevalence of Enhancer of Zeste Homolog 2 in Patients with Resected Small Cell Lung Cancer.

Toyokawa G, Takada K, Tagawa T, Kinoshita F, Kozuma Y, Matsubara T, Haratake N, Takamori S, Akamine T, Hirai F, Yamada Y, Hamamoto R, Oda Y, Maehara Y.

Anticancer Res. 2018 Jun;38(6):3707-3711. doi: 10.21873/anticanres.12649.

PMID:
29848731
48.

The significant influence of having children on the postoperative prognosis of patients with nonsmall cell lung cancer: A propensity score-matched analysis.

Takamori S, Tagawa T, Toyokawa G, Ueo H, Shimokawa M, Kinoshita F, Matsubara T, Kozuma Y, Haratake N, Akamine T, Katsura M, Takada K, Hirai F, Shoji F, Okamoto T, Oda Y, Maehara Y.

Cancer Med. 2018 May 29. doi: 10.1002/cam4.1539. [Epub ahead of print]

49.

Microfluidic PCR Amplification and MiSeq Amplicon Sequencing Techniques for High-Throughput Detection and Genotyping of Human Pathogenic RNA Viruses in Human Feces, Sewage, and Oysters.

Oshiki M, Miura T, Kazama S, Segawa T, Ishii S, Hatamoto M, Yamaguchi T, Kubota K, Iguchi A, Tagawa T, Okubo T, Uemura S, Harada H, Kobayashi N, Araki N, Sano D.

Front Microbiol. 2018 Apr 27;9:830. doi: 10.3389/fmicb.2018.00830. eCollection 2018.

50.

Significance of Spread Through Air Spaces in Resected Lung Adenocarcinomas With Lymph Node Metastasis.

Toyokawa G, Yamada Y, Tagawa T, Kinoshita F, Kozuma Y, Matsubara T, Haratake N, Takamori S, Akamine T, Hirai F, Oda Y, Maehara Y.

Clin Lung Cancer. 2018 Sep;19(5):395-400.e1. doi: 10.1016/j.cllc.2018.04.002. Epub 2018 Apr 18.

PMID:
29735272

Supplemental Content

Loading ...
Support Center